Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Bababeygy SR et al. - The authors conclude that in cases of cutaneous MRSA infections that respond poorly to vancomycin, linezolid and rifampin combination therapy may provide an alternative therapeutic option.

Related Articles

Severe pruritic rash, fever, and malaise
The Clinical Advisor, 11/10/09    Relevance Score: 67%

Comparative Assessment of Antimicrobial Activities of Antibiotic-Treated Penile Prostheses
European Urology, 11/10/09    Relevance Score: 65%

Efficacy of High Doses of Daptomycin versus Alternative Therapies against Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus
Antimicrobial Agents and Chemotherapy, 10/06/09    Relevance Score: 64%

Update on 2009 pandemic influenza A (H1N1) virus
Cleveland Clinic Journal of Medicine, 10/05/09    Relevance Score: 49%

The usefulness of a free self-test for screening albuminuria in the general population: a cross-sectional survey
BMC Public Health, 10/15/09    Relevance Score: 48%

Today in Drug Interactions...keeping you current

'Party pill' drugs - BZP and TFMPP
New Zealand Medical Journal, 12/14/09

A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism
Alimentary Pharmacology and Therapeutics, 12/10/09

Combination of intensive cognitive rehabilitation and donepezil therapy in Alzheimer's disease (AD)
Archives of Gerontology and Geriatrics, 12/09/09

Today in Other Drugs...keeping you current

Chitosan-tripolyphosphate nanoparticles as a possible skin drug delivery system for aciclovir with enhanced stability
Journal of Pharmacy and Pharmacology, 12/15/09

Novel TNF antagonists for the treatment of rheumatoid arthritis
Expert Opinion on Investigational Drugs, 12/15/09

Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid Arthritis
Genentech, 12/15/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address